Telehealth company Hims & Hers reported first-quarter results late Monday that beat Wall Street estimates. But parts of the ...

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...

Hims & Hers Health (NYSE: HIMS) stock surged 23% on Tuesday, April 29, after Novo Nordisk announced plans to offer popular ...

Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Hims & Hers stock was trading lower but has since reversed and began trading higher after the company reported first-quarter ...

Hims & Hers Health (HIMS) stock is getting attention from options bulls after beating first-quarter expectations ...

Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft ...

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

Following these developments, HIMS stock rose over 3% to $42.19, reflecting investor confidence in the company’s strategic direction. Hims & Hers has guided for FY25 revenue between $1.17 billion and ...

Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting results tomorrow after the bell. Here’s what investors ...